Cargando…
P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431134/ http://dx.doi.org/10.1097/01.HS9.0000971364.86087.32 |
Sumario: |
---|